Bulk AD brain homogenate treatment led to a 20–30% synapse loss in the iPSC-derived cortical neurons regardless of their MAPT genotypes or the presence of Aβ (Supplementary Fig. 7C; Exon 4). The gene discussed is MAPT; the disease is Alzheimer disease.